Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Down 5.50%
As of Friday, October 16, Capricor Therapeutics, Inc.’s CAPR share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Commentary & Analysis
Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Up 5.92%
As of Thursday, October 15, Capricor Therapeutics, Inc.’s CAPR share price has surged by 5.92%, which has investors questioning if this is right time to sell.Michael Rose
Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Down 5.74%
As of Wednesday, October 14, Capricor Therapeutics, Inc.’s CAPR share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Down 5.81%
As of Monday, October 05, Capricor Therapeutics, Inc.’s CAPR share price has dipped by 5.81%, which has investors questioning if this is right time to buy.Michael Rose
Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Down 5.28%
As of Thursday, October 01, Capricor Therapeutics, Inc.’s CAPR share price has dipped by 5.28%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $390.1 | $208.8 | 35% |
|
| Shares Out (Mil) | 57.9 | 53.9 | 51% |
|
| Institutional Ownership | 98.5% | 93.1% | 79% |
|
| Float (Mil) | 45.5 | 41.4 | 45% |
|
| Beta | 0.53 | 0.95 | 30% |
|
| Avg Daily Volume (000s) | 2,895 | 614 | 86% |
|
| Price Change (52-week) |
0.2% | 45.3% | 53% |
|
| Growth | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (50.3%) | (10.2%) | 7% |
|
| EPS (5yr) | (20.8%) | 15.7% | 13 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 26.3% | (15.7%) | 84% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 9 | |
| Current EPS | ($0.409) | ($1.452) | ($1.451) | |
| Month Ago EPS | ($0.420) | ($1.452) | ($1.478) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.346 | ($0.222) | ($0.642) | |
| Year/Year Chg | (41.8%) | (35.8%) | (101.1%) | |
| Financials | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($129) | ($44) | 9% |
|
| EPS (TTM) | ($2.466) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($104) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $2 | 37% |
|
| Long-Term Debt (Q1) (Mil) | $90 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $240 | $174 | 27% |
|
| Valuation | CAPR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.58 | 2.09 | 45% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (51.5%) | (47.2%) | 11% |
|
| ROE | (73.7%) | (54.2%) | 12% |
|
| Liabilities to Assets | 33.2% | 29.1% | 24% |
|
| F-Score | 3 | 2 | 18% |
|
Capricor Therapeutics, Inc. did not pass any screens on 10/16/2026.
